Tenon Medical, Inc. TNON
We take great care to ensure that the data presented and summarized in this overview for Tenon Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TNON
Top Purchases
Top Sells
About TNON
Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and corresponding outcomes. It sells The CATAMARAN SIJ Fusion System that includes instruments and implants designed to prepare and fixate the SI-Joint for fusion in the United States and Puerto Rico. The company was founded in 2012 and is based in Los Gatos, California.
Insider Transactions at TNON
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2026
|
Ivan Howard Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,327
-28.22%
|
$0
$0.93 P/Share
|
|
Jan 05
2026
|
Kevin Williamson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,518
-30.32%
|
$0
$0.93 P/Share
|
|
Jan 05
2026
|
Richard Ginn Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
47,426
-35.65%
|
$0
$0.93 P/Share
|
|
Jan 05
2026
|
Robert K Weigle Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,413
-31.13%
|
$0
$0.93 P/Share
|
|
Jan 05
2026
|
Stephen Hochschuler Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,327
-29.53%
|
$0
$0.93 P/Share
|
|
Jan 01
2026
|
Ivan Howard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,732
+47.65%
|
-
|
|
Jan 01
2026
|
Kevin Williamson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
58,987
+49.13%
|
-
|
|
Jan 01
2026
|
Kristine M Jacques Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,729
+27.58%
|
-
|
|
Jan 01
2026
|
Richard Ferrari Director |
BUY
Exercise of conversion of derivative security
|
Direct |
64,478
+47.68%
|
-
|
|
Jan 01
2026
|
Richard Ginn Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
126,577
+48.76%
|
-
|
|
Jan 01
2026
|
Robert K Weigle Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,732
+49.46%
|
-
|
|
Jan 01
2026
|
Stephen Hochschuler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,732
+48.79%
|
-
|
|
Jan 01
2026
|
Steven M Foster CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
140,936
+46.25%
|
-
|
|
Nov 14
2025
|
Steven M Foster CEO and President |
BUY
Open market or private purchase
|
Direct |
19,455
+45.96%
|
-
|
|
Nov 14
2025
|
Nathaniel A. Grawey Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
101,167
+29.72%
|
-
|
|
Nov 14
2025
|
Wyatt D. Geist Chief Innovation Officer |
BUY
Open market or private purchase
|
Direct |
19,455
+10.99%
|
-
|
|
Sep 03
2025
|
Kevin Williamson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,083
+50.0%
|
-
|
|
May 22
2025
|
Ivan Howard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
78
+6.87%
|
-
|
|
May 22
2025
|
Robert K Weigle Director |
BUY
Exercise of conversion of derivative security
|
Direct |
78
+25.08%
|
-
|
|
May 22
2024
|
Ivan Howard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
78
+7.38%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 436K shares |
|---|---|
| Open market or private purchase | 140K shares |
| Payment of exercise price or tax liability | 76K shares |
|---|